HomeUSAVisiRose Raises $3M in Seed Financing

VisiRose Raises $3M in Seed Financing

-

visirose

VisiRose, a Knoxville, TN-based clinical-stage biotechnology company, raised $3M in Seed funding.

Backers were not disclosed.

The company intends to use the funds to support new initiatives, including:

  • Completing a pre-investigational new drug (IND) submission meeting with the U.S. Food and Drug Administration (FDA) for its Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a non-invasive, investigational treatment for infectious keratitis and other serious eye infections.
  • Submitting an IND application for investigational drug PV-305, targeting corneal blindness (RB) through photodynamic therapy (PDAT), and working toward its acceptance by the FDA.
  • Manufacturing an initial clinical supply of PV-305, enabling the company to initiate clinical trials.

Led by CEO Dominic Rodrigues, VisiRose is leveraging a new ocular RB PDAT research from the University of Miami’s Bascom Palmer Eye Institute and Ophthalmic Biophysics Center, in collaboration with Provectus Biopharmaceuticals (OTCQB: PVCT). At the heart of its therapeutic platform is Provectus’s bioactive synthetic small molecule, Rose Bengal Sodium (RBS), to treat a range of sight-threatening ocular conditions with high unmet medical needs.

FinSMEs

16/01/2025

THE DAILY NEWSLETTER - SIGNUP